These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone. Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398 [TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments. Tang F; Ng CM; Bada HS; Leggas M Clin Transl Sci; 2021 Jul; 14(4):1231-1249. PubMed ID: 33650314 [TBL] [Abstract][Full Text] [Related]
24. Pregnancy Alters CYP- and UGT-Mediated Metabolism of Buprenorphine. Zhang H; Bastian JR; Zhao W; Chen H; Shaik IH; Chaphekar N; Caritis SN; Venkataramanan R Ther Drug Monit; 2020 Apr; 42(2):264-270. PubMed ID: 31929398 [TBL] [Abstract][Full Text] [Related]
25. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. Kraft WK; Adeniyi-Jones SC; Chervoneva I; Greenspan JS; Abatemarco D; Kaltenbach K; Ehrlich ME N Engl J Med; 2017 Jun; 376(24):2341-2348. PubMed ID: 28468518 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder. Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606 [TBL] [Abstract][Full Text] [Related]
29. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. Gaalema DE; Scott TL; Heil SH; Coyle MG; Kaltenbach K; Badger GJ; Arria AM; Stine SM; Martin PR; Jones HE Addiction; 2012 Nov; 107 Suppl 1(0 1):53-62. PubMed ID: 23106927 [TBL] [Abstract][Full Text] [Related]
31. Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants. Devlin LA; Young LW; Kraft WK; Wachman EM; Czynski A; Merhar SL; Winhusen T; Jones HE; Poindexter BB; Wakschlag LS; Salisbury AL; Matthews AG; Davis JM J Perinatol; 2022 Mar; 42(3):300-306. PubMed ID: 34556799 [TBL] [Abstract][Full Text] [Related]
32. Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction. Fihlman M; Hemmilä T; Hagelberg NM; Kuusniemi K; Backman JT; Laitila J; Laine K; Neuvonen PJ; Olkkola KT; Saari TI Eur J Clin Pharmacol; 2016 Nov; 72(11):1363-1371. PubMed ID: 27510521 [TBL] [Abstract][Full Text] [Related]
33. Newborn Cry Acoustics in the Assessment of Neonatal Opioid Withdrawal Syndrome Using Machine Learning. Manigault AW; Sheinkopf SJ; Silverman HF; Lester BM JAMA Netw Open; 2022 Oct; 5(10):e2238783. PubMed ID: 36301544 [TBL] [Abstract][Full Text] [Related]
39. A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4. Liu T; Gobburu JVS J Pharm Sci; 2018 Mar; 107(3):942-948. PubMed ID: 29102550 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers. Bai SA; Xiang Q; Finn A Clin Ther; 2016 Feb; 38(2):358-69. PubMed ID: 26804639 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]